Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Controlling Extra- and Intramacrophagic Mycobacterium abscessus by Targeting Mycolic Acid Transport.

Viljoen A, Herrmann JL, Onajole OK, Stec J, Kozikowski AP, Kremer L.

Front Cell Infect Microbiol. 2017 Sep 1;7:388. doi: 10.3389/fcimb.2017.00388. eCollection 2017.

2.

Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections.

Kozikowski AP, Onajole OK, Stec J, Dupont C, Viljoen A, Richard M, Chaira T, Lun S, Bishai W, Raj VS, Ordway D, Kremer L.

J Med Chem. 2017 Jul 13;60(13):5876-5888. doi: 10.1021/acs.jmedchem.7b00582. Epub 2017 Jun 15.

PMID:
28574259
3.

Structure and Dynamics of the Liver Receptor Homolog 1-PGC1α Complex.

Mays SG, Okafor CD, Tuntland ML, Whitby RJ, Dharmarajan V, Stec J, Griffin PR, Ortlund EA.

Mol Pharmacol. 2017 Jul;92(1):1-11. doi: 10.1124/mol.117.108514. Epub 2017 Mar 31.

4.

Crystal Structures of the Nuclear Receptor, Liver Receptor Homolog 1, Bound to Synthetic Agonists.

Mays SG, Okafor CD, Whitby RJ, Goswami D, Stec J, Flynn AR, Dugan MC, Jui NT, Griffin PR, Ortlund EA.

J Biol Chem. 2016 Dec 2;291(49):25281-25291. Epub 2016 Sep 30.

5.

Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.

Stec J, Onajole OK, Lun S, Guo H, Merenbloom B, Vistoli G, Bishai WR, Kozikowski AP.

J Med Chem. 2016 Jul 14;59(13):6232-47. doi: 10.1021/acs.jmedchem.6b00415. Epub 2016 Jun 22.

PMID:
27275668
6.

Phenotypic and Molecular Antibiotic Resistance Determination of Airborne Coagulase Negative Staphylococcus spp. Strains from Healthcare Facilities in Southern Poland.

Lenart-Boroń A, Wolny-Koładka K, Stec J, Kasprowic A.

Microb Drug Resist. 2016 Oct;22(7):515-522. Epub 2016 Mar 15.

PMID:
26978225
7.

Patients' satisfaction with therapy methods of advanced chronic venous disease.

Chudek J, Mikosiński J, Kobielski A, Hering A, Aleksiejew-Kleszczyński T, Umiński J, Zubilewicz T, Kobusiewicz W, Iłżecki M, Wojtak A, Stec J, Urbanek T.

Int Angiol. 2016 Feb;35(1):98-107. Epub 2015 Sep 25.

PMID:
26406967
8.

Recently disclosed chemical entities as potential candidates for management of tuberculosis.

Stec J, Abourashed EA.

Pharm Pat Anal. 2015;4(4):317-47. doi: 10.4155/ppa.15.13. Review.

PMID:
26174569
9.

Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.

Stec J, Vilchèze C, Lun S, Perryman AL, Wang X, Freundlich JS, Bishai W, Jacobs WR Jr, Kozikowski AP.

ChemMedChem. 2014 Nov;9(11):2528-37. doi: 10.1002/cmdc.201402255. Epub 2014 Aug 27.

10.

Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.

Afanador GA, Muench SP, McPhillie M, Fomovska A, Schön A, Zhou Y, Cheng G, Stec J, Freundlich JS, Shieh HM, Anderson JW, Jacobus DP, Fidock DA, Kozikowski AP, Fishwick CW, Rice DW, Freire E, McLeod R, Prigge ST.

Biochemistry. 2013 Dec 23;52(51):9155-66. doi: 10.1021/bi400945y. Epub 2013 Dec 13.

11.

Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.

Stec J, Fomovska A, Afanador GA, Muench SP, Zhou Y, Lai BS, El Bissati K, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Sommervile C, Woods S, Roberts CW, Rice D, Prigge ST, McLeod R, Kozikowski AP.

ChemMedChem. 2013 Jul;8(7):1138-60. doi: 10.1002/cmdc.201300050. Epub 2013 Jun 14.

12.

Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.

Muench SP, Stec J, Zhou Y, Afanador GA, McPhillie MJ, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Prigge ST, Rice DW, McLeod R.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3551-5. doi: 10.1016/j.bmcl.2013.04.035. Epub 2013 Apr 24.

13.

Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.

Onajole OK, Pieroni M, Tipparaju SK, Lun S, Stec J, Chen G, Gunosewoyo H, Guo H, Ammerman NC, Bishai WR, Kozikowski AP.

J Med Chem. 2013 May 23;56(10):4093-103. doi: 10.1021/jm4003878. Epub 2013 May 3.

PMID:
23611124
14.

The first total synthesis of (+)-mucosin.

Henderson AR, Stec J, Owen DR, Whitby RJ.

Chem Commun (Camb). 2012 Apr 7;48(28):3409-11. doi: 10.1039/c2cc17915f. Epub 2012 Feb 22.

PMID:
22358150
15.

Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway.

Fomovska A, Huang Q, El Bissati K, Mui EJ, Witola WH, Cheng G, Zhou Y, Sommerville C, Roberts CW, Bettis S, Prigge ST, Afanador GA, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Pieroni M, Stec J, Muench SP, Rice DW, Kozikowski AP, McLeod R.

Antimicrob Agents Chemother. 2012 May;56(5):2666-82. doi: 10.1128/AAC.06450-11. Epub 2012 Feb 21.

16.

Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania.

Stec J, Huang Q, Pieroni M, Kaiser M, Fomovska A, Mui E, Witola WH, Bettis S, McLeod R, Brun R, Kozikowski AP.

J Med Chem. 2012 Apr 12;55(7):3088-100. doi: 10.1021/jm2015183. Epub 2012 Mar 20.

17.

Tandem insertion of halocarbenoids and lithium acetylides into zirconacycles: a novel rearrangement to zirconium alkenylidenates by β-addition to an alkynyl zirconocene.

Stec J, Thomas E, Dixon S, Whitby RJ.

Chemistry. 2011 Apr 18;17(17):4896-904. doi: 10.1002/chem.201002962. Epub 2011 Mar 21.

PMID:
21425365
18.

Small molecule agonists of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2).

Whitby RJ, Stec J, Blind RD, Dixon S, Leesnitzer LM, Orband-Miller LA, Williams SP, Willson TM, Xu R, Zuercher WJ, Cai F, Ingraham HA.

J Med Chem. 2011 Apr 14;54(7):2266-81. doi: 10.1021/jm1014296. Epub 2011 Mar 10.

19.

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M.

Ann Oncol. 2006 May;17(5):813-7. Epub 2006 Jan 10.

PMID:
16403809
20.

A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.

Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L.

Endocr Relat Cancer. 2005 Dec;12(4):1059-69.

21.

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L.

Clin Cancer Res. 2005 Aug 15;11(16):5678-85.

22.

Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips.

Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell S, Linette G, Hortobagyi GN, Fraser Symmans W, Pusztai L.

J Mol Diagn. 2005 Aug;7(3):357-67.

23.

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD.

Br J Haematol. 2005 Jun;129(6):755-62.

PMID:
15953001
24.

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8315-20. Epub 2005 May 24.

25.

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI.

Clin Cancer Res. 2005 Mar 15;11(6):2149-55.

26.

Targeted therapies for cancer 2004.

Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN.

Am J Clin Pathol. 2004 Oct;122(4):598-609. Review.

PMID:
15487459
27.

DNA ploidy and cell cycle analysis in breast cancer.

Ross JS, Linette GP, Stec J, Ross MS, Anwar S, Boguniewicz A.

Am J Clin Pathol. 2003 Dec;120 Suppl:S72-84. Review.

PMID:
15298145
28.

HER-2/neu testing in breast cancer.

Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN.

Am J Clin Pathol. 2003 Dec;120 Suppl:S53-71. Review.

PMID:
15298144
29.

Pharmacogenomics.

Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN.

Adv Anat Pathol. 2004 Jul;11(4):211-20. Review.

PMID:
15220824
30.

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2004 Jun 15;22(12):2284-93. Epub 2004 May 10.

PMID:
15136595
31.

Breast cancer biomarkers and molecular medicine: part II.

Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L.

Expert Rev Mol Diagn. 2004 Mar;4(2):169-88. Review.

PMID:
14995904
32.

Targeted therapy in breast cancer: the HER-2/neu gene and protein.

Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN.

Mol Cell Proteomics. 2004 Apr;3(4):379-98. Epub 2004 Feb 3. Review.

33.

Breast cancer biomarkers and molecular medicine.

Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L.

Expert Rev Mol Diagn. 2003 Sep;3(5):573-85. Review.

PMID:
14510178
34.
35.

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ.

Oncologist. 2003;8(4):307-25. Review.

36.

Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF.

Clin Cancer Res. 2003 Jul;9(7):2406-15.

37.

Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.

Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L.

Cancer. 2003 Jun 15;97(12):2960-71.

38.

Clinical application of cDNA microarrays in oncology.

Pusztai L, Ayers M, Stec J, Hortobágyi GN.

Oncologist. 2003;8(3):252-8. Review.

39.

Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.

Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L.

Cancer J. 2002 Nov-Dec;8(6):461-8.

PMID:
12500855
40.

Single- vs. multiple-set strength training in women.

Schlumberger A, Stec J, Schmidtbleicher D.

J Strength Cond Res. 2001 Aug;15(3):284-9.

PMID:
11710652
41.

Effect of marathon running on inflammatory and hemostatic markers.

Siegel AJ, Stec JJ, Lipinska I, Van Cott EM, Lewandrowski KB, Ridker PM, Tofler GH.

Am J Cardiol. 2001 Oct 15;88(8):918-20, A9. No abstract available.

PMID:
11676965
42.

The effect of vitamin C supplementation on coagulability and lipid levels in healthy male subjects.

Tofler GH, Stec JJ, Stubbe I, Beadle J, Feng D, Lipinska I, Taylor A.

Thromb Res. 2000 Oct 1;100(1):35-41.

PMID:
11053614
43.

Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population.

Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, Wilson PF, Muller JE, D'Agostino RB Sr.

Circulation. 2000 Oct 3;102(14):1634-8.

44.

Cocaine-induced erythrocytosis and increase in von Willebrand factor: evidence for drug-related blood doping and prothrombotic effects.

Siegel AJ, Sholar MB, Mendelson JH, Lukas SE, Kaufman MJ, Renshaw PF, McDonald JC, Lewandrowski KB, Apple FS, Stec JJ, Lipinska I, Tofler GH, Ridker PM.

Arch Intern Med. 1999 Sep 13;159(16):1925-9.

PMID:
10493323
46.
47.

Zinc and copper metabolism in nephrotic syndrome.

Stec J, Podracká L, Pavkovceková O, Kollár J.

Nephron. 1990;56(2):186-7.

PMID:
2243574
48.

[Renal excretion of zinc in children with kidney diseases].

Stec J, Podracká L, Pavkovceková O.

Cesk Pediatr. 1989 Dec;44(12):705-7. Slovak.

PMID:
2636552
49.
50.

Activation of a low specific activity form of DNA polymerase alpha by inositol-1,4-bisphosphate.

Sylvia V, Curtin G, Norman J, Stec J, Busbee D.

Cell. 1988 Aug 26;54(5):651-8.

PMID:
2842061

Supplemental Content

Support Center